Synthesis, biological activity and molecular modeling of 4-fluoro-N-[ω-(1,2,3,4-tetrahydroacridin-9-ylamino)-alkyl]-benzamide derivatives as cholinesterase inhibitors

Arzneimittel-Forschung/Drug Research

Volumn 62, Issue 12, 2012, Pages 655-660

  Szymanski P ^a   Markowicz, M ^a   Bajda, M ^b   Malawska, B ^b   Mikiciuk Olasik, E ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Alzheimers disease; docking; Ellmans method; fluorobenzoic acid; tacrine

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 FLUORO [ OMEGA (1,2,3,4 TETRAHYDROACRIDIN 9 YLAMINO) ALKYL] BENZAMIDE DERIVATIVE; ACETYLCHOLINESTERASE; BENZAMIDE DERIVATIVE; CHLORIDE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; METRIFONATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENSERINE; RIVASTIGMINE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BIOLOGICAL ACTIVITY; CHEMICAL REACTION; CHOLINESTERASE INHIBITION; CRYSTALLIZATION; DISEASE COURSE; DRUG ACTIVITY; DRUG CONFORMATION; DRUG SYNTHESIS; ENZYME ACTIVITY; HUMAN; HYDROLYSIS; IC 50; MOLECULAR MODEL; NEUROIMAGING; NEUROPROTECTION; PATHOGENESIS; SPECTROMETRY; TREATMENT INDICATION;

ACETYLCHOLINESTERASE; ANIMALS; BENZAMIDES; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; ELECTROPHORUS; INDICATORS AND REAGENTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; SPECTROPHOTOMETRY, ULTRAVIOLET; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84871830159     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0032-1329963     Document Type: Article

References (30)

1. Blennow K., de Leon M. J., Zetterberg H. Alzheimers disease. Lancet: 2006; 368 387 403
2. Weiner M. W., Aisen P. S., Jack C. R. et al. The Alzheimers disease neuroimaging initiative: progress report and future plans. Alzheimer Dement: 2010; 6 202 211
3. Mucke L. Neuroscience: Alzheimers disease. Nature: 2009; 461 895 897
4. Petrella J. R., Coleman E., Doraiswamy P. M. Neuroimaging and Early Diagnosis of Alzheimer Disease. Radiology: 2003; 226 315 336 (Pubitemid 36313415)
5. Greig N. H., Utsuki T., Ingram D. K. et al. Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer -amyloid peptide in rodent. P Natl Acad Sci: 2005; 102 47 17213 17218 (Pubitemid 41692709)
6. 18F]fluoro-CP-118,954 for the in vivo mapping of acetylcholinesterase. Nucl Med Biol: 2005; 32 185 191 (Pubitemid 40260670)
7. Tavitian B., Pappata S., Bonnot-Lours S. et al. Positron emission tomography study of [11C]methyl-tetrahydroaminoacridine (methyl-tacrine) in baboon brain. Eur J Pharmacol: 1993; 236 229 238 (Pubitemid 23158301)
8. Pappata S., Tavitian B., Traykov L. et al. In Vivo Imaging of Human Cerebral Acetylcholinesterase. J Neurochem: 1996; 67 876 879 (Pubitemid 26255688)
9. Lee S-Y, Choe Y. S., Sugimoto H. et al. Synthesis and biological evaluation of 1-(4-[18F]fluorobenzyl)-4- [(5,6-dimethoxy-1-oxoindan-2-yl)methyl] piperidine for in vivo studies of acetylcholinesterase. Nucl Med Biol: 2000; 27 741 744 (Pubitemid 32058811)
10. Choe Y. S., Oh S. J., Shim I. et al. Syntheses and biological evaluation of 18F-labeled 3-(1-benzylpiperidin-4-yl)-1-(1-methyl-1H-indol-3-yl)propan-1- ones for in vivo mappingof acetylcholinesterase. Nucl Med Biol: 2000; 27 263 267 (Pubitemid 30314720)
11. Liston D. R., Nielsen J. A., Villalobos A. et al. Pharmacology of selective acetylcholinesterase inhibitors: Implications for use in Alzheimers disease. Eur J Pharmacol: 2004; 486 9 17 (Pubitemid 38130155)
12. Pakaski M., Kalman J. Interactions between the amyloid and cholinergic mechanisms in Alzheimers disease. Neurochem Int: 2008; 53 103 111
13. Sabbagh N. M., Richardson S., Relkin N. Disease-modifying approaches to Alzheimers disease: Challenges and opportunities-lessons from donepezil therapy. Alzheimer Dement: 2008; 4 109 118
14. Hagmann W. K. The Effect of Fluorine Substitution on. pKa. J Med Chem: 2008; 51 4359 4369
15. Hu M-K, Wu L-J, Hsiao G. et al. Homodimeric Tacrine Congeners as Acetylcholinesterase Inhibitors. J Med Chem: 2002; 11 2277 2282 (Pubitemid 34525807)
16. Szymański P., Karpiski A., Mikiciuk-Olasik E. Synthesis, biological activity and HPLC validation of 1,2,3,4-tetrahydroacridine derivatives as acetylcholinesterase inhibitors. Eur J Med Chem: 2011; 46 3250 3257
17. Carlier P. R., Du D. M., Han Y. et al. Potent, Easily Synthesized Huperzine A-Tacrine Hybrid Acetylcholinesterase Inhibitors. Bioorg Med Chem Lett Aug: 1999; 9 16 2335 2338 (Pubitemid 29391517)
18. Szymanski P., Markowicz M., Mikiciuk-Olasik E. Synthesis and biological activity of derivatives of tetrahydroacridine as acetylcholinesterase inhibitors. Bioorg Chem: 2011; 39 04 138 142
19. Dorronsoro I., Alonso D., Castro A. et al. Synthesis and Biological Evaluation of Tacrine-Thiadiazolidinone Hybrids as Dual Acetylcholinesterase Inhibitors. Arch Pharm Chem Life Sci: 2005; 338 18 23 (Pubitemid 40364647)
20. Carlier P. R., Han Y. F., Chow ES-W et al. Evaluation of short-tether Bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Bioorg Med Chem: 1999; 7 351 357 (Pubitemid 29117099)
21. Rosini M., Andrisano V., Bartolini M. et al. Rational Approach to discover multipotent anti-Alzheimer drugs. J Med Chem: 2005; 48 360 363 (Pubitemid 40139781)
22. Fang L., Kraus B., Lehmann J. et al. Tacrine-ferulic Acid Hybrids as Multi-potent Anti-Alzheimer Drug Candidates. Bioorg Med Chem: 2008; 18 2905 2909 (Pubitemid 351608873)
23. Carlier P. R., Chow ES-W, Han Y. F. et al. Heterodimeric Tacrine-Based Acetylcholinesterase Inhibitors: Investigating Ligand Peripheral Site Interactions. J Med Chem: 1999; 42 4225 4231 (Pubitemid 29483039)
24. Fang L., Appenroth D., Decker M. et al. Tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity. J Med Chem: 2008; 51 7666 7669
25. Kamiski Z. J. 2-Chloro-4,6-dimethoxy-1,3,5-triazine. A New Coupling Reagent for Peptide Synthesis. Synthesis: 1987; 917 920
26. Blotny G. Recent applications of 2,4,6-trichloro-1,3,5-triazine and its derivatives in organic synthesis. Tetrahedron: 2006; 62 9507 9522 (Pubitemid 44389730)
27. Ellman G. L., Courtney K. D., Andres V. et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharm: 1961; 7 88 95
28. Cheng Y. C., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharm: 1973; 22 3099 3108
29. Tipton K. F. Commentary: Enzyme kinetics in relation to enzyme inhibitors. Biochem Pharm: 1973; 22 2933 2941
30. Szymański P., Markowicz M., Bajda M. et al. Synthesis and biological activity of new 2,3-dihydro-1H-cyclopenta[b]quinoline derivatives as acetylcholinesterase inhibitors. Lett Drug Des Discov: 2012; 9 645 654